Waters Corporation (NYSE: WAT) Stock Competitors & Peer Comparison
See WAT's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for WAT and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| WAT | $460.34 | +1.04% | 44.5B | 33.16 | $13.68 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.67% |
| TMO | $682.94 | +0.95% | 249.2B | 29.10 | $23.16 | +0.27% |
| DHR | $233.52 | +1.64% | 162B | 28.88 | $7.98 | +0.67% |
| NTRA | $407.11 | +1.43% | 58.2B | -306.02 | -$1.32 | N/A |
| A | $176.04 | +1.23% | 48.8B | 29.78 | $5.81 | +0.59% |
| IQV | $280.73 | +0.87% | 46B | 23.03 | $12.13 | N/A |
| IDXX | $568.63 | +0.33% | 44.1B | 39.41 | $14.22 | N/A |
| ILMN | $273.32 | +1.46% | 40.7B | 53.56 | $5.03 | N/A |
| MTD | $1,677.91 | -0.40% | 33.4B | 38.35 | $43.51 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
WAT vs DHR-PB Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, WAT's ROE is +0.02%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, WAT is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for WAT.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
WAT vs TMO Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, TMO has a market cap of 249.2B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while TMO trades at $682.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas TMO's P/E ratio is 29.10. In terms of profitability, WAT's ROE is +0.02%, compared to TMO's ROE of +0.13%. Regarding short-term risk, WAT is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for WAT.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
WAT vs DHR Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, DHR has a market cap of 162B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while DHR trades at $233.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas DHR's P/E ratio is 28.88. In terms of profitability, WAT's ROE is +0.02%, compared to DHR's ROE of +0.08%. Regarding short-term risk, WAT is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for WAT.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
WAT vs NTRA Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, NTRA has a market cap of 58.2B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while NTRA trades at $407.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas NTRA's P/E ratio is -306.02. In terms of profitability, WAT's ROE is +0.02%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, WAT is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for WAT.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
WAT vs A Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, A has a market cap of 48.8B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while A trades at $176.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas A's P/E ratio is 29.78. In terms of profitability, WAT's ROE is +0.02%, compared to A's ROE of +0.20%. Regarding short-term risk, WAT is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for WAT.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
WAT vs IQV Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, IQV has a market cap of 46B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while IQV trades at $280.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas IQV's P/E ratio is 23.03. In terms of profitability, WAT's ROE is +0.02%, compared to IQV's ROE of +0.22%. Regarding short-term risk, WAT is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for WAT.Check IQV's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
WAT vs IDXX Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, IDXX has a market cap of 44.1B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while IDXX trades at $568.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas IDXX's P/E ratio is 39.41. In terms of profitability, WAT's ROE is +0.02%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, WAT is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for WAT.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
WAT vs ILMN Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, ILMN has a market cap of 40.7B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while ILMN trades at $273.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas ILMN's P/E ratio is 53.56. In terms of profitability, WAT's ROE is +0.02%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, WAT is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for WAT.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
WAT vs MTD Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, MTD has a market cap of 33.4B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while MTD trades at $1,677.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas MTD's P/E ratio is 38.35. In terms of profitability, WAT's ROE is +0.02%, compared to MTD's ROE of -12.00%. Regarding short-term risk, WAT is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for WAT.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
WAT vs DGX Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, DGX has a market cap of 26.7B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while DGX trades at $243.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas DGX's P/E ratio is 23.85. In terms of profitability, WAT's ROE is +0.02%, compared to DGX's ROE of +0.15%. Regarding short-term risk, WAT is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for WAT.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
WAT vs LH Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, LH has a market cap of 26.7B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while LH trades at $329.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas LH's P/E ratio is 19.53. In terms of profitability, WAT's ROE is +0.02%, compared to LH's ROE of +0.12%. Regarding short-term risk, WAT is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for WAT.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
WAT vs GH Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, GH has a market cap of 22.7B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while GH trades at $174.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas GH's P/E ratio is -48.45. In terms of profitability, WAT's ROE is +0.02%, compared to GH's ROE of +2.11%. Regarding short-term risk, WAT is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for WAT.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
WAT vs EXAS Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas EXAS's P/E ratio is -95.37. In terms of profitability, WAT's ROE is +0.02%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, WAT is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for WAT.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
WAT vs MEDP Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, MEDP has a market cap of 18.7B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while MEDP trades at $675.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas MEDP's P/E ratio is 39.23. In terms of profitability, WAT's ROE is +0.02%, compared to MEDP's ROE of +1.00%. Regarding short-term risk, WAT is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for WAT.Check MEDP's competition here
Revvity, Inc. (NYSE: RVTY)
WAT vs RVTY Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, RVTY has a market cap of 17.7B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while RVTY trades at $161.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas RVTY's P/E ratio is 29.67. In terms of profitability, WAT's ROE is +0.02%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, WAT is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for WAT.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
WAT vs ILMNV Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas ILMNV's P/E ratio is N/A. In terms of profitability, WAT's ROE is +0.02%, compared to ILMNV's ROE of N/A. Regarding short-term risk, WAT is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for WAT.Check ILMNV's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
WAT vs CRL Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, CRL has a market cap of 16.6B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while CRL trades at $356.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas CRL's P/E ratio is 34.87. In terms of profitability, WAT's ROE is +0.02%, compared to CRL's ROE of -0.08%. Regarding short-term risk, WAT is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for WAT.Check CRL's competition here
PerkinElmer, Inc. (NYSE: PKI)
WAT vs PKI Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas PKI's P/E ratio is 41.45. In terms of profitability, WAT's ROE is +0.02%, compared to PKI's ROE of +0.03%. Regarding short-term risk, WAT is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for WAT.Check PKI's competition here
ICON Public Limited Company (NASDAQ: ICLR)
WAT vs ICLR Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, ICLR has a market cap of 14.3B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while ICLR trades at $184.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas ICLR's P/E ratio is 15.11. In terms of profitability, WAT's ROE is +0.02%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, WAT is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for WAT.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
WAT vs QGEN Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, QGEN has a market cap of 10.4B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while QGEN trades at $50.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas QGEN's P/E ratio is 20.82. In terms of profitability, WAT's ROE is +0.02%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, WAT is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for WAT.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
WAT vs GRAL Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, GRAL has a market cap of 5.9B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while GRAL trades at $141.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas GRAL's P/E ratio is -13.59. In terms of profitability, WAT's ROE is +0.02%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, WAT is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for WAT.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
WAT vs RDNT Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, RDNT has a market cap of 5.5B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while RDNT trades at $71.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas RDNT's P/E ratio is 152.91. In terms of profitability, WAT's ROE is +0.02%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, WAT is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for WAT.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
WAT vs SHC Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while SHC trades at $18.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas SHC's P/E ratio is 18.85. In terms of profitability, WAT's ROE is +0.02%, compared to SHC's ROE of +0.27%. Regarding short-term risk, WAT is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for WAT.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
WAT vs BLLN Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, BLLN has a market cap of 5.1B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while BLLN trades at $110.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas BLLN's P/E ratio is 153.96. In terms of profitability, WAT's ROE is +0.02%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, WAT is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for WAT.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
WAT vs SYNH Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas SYNH's P/E ratio is 61.40. In terms of profitability, WAT's ROE is +0.02%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, WAT is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for WAT.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
WAT vs VCYT Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, VCYT has a market cap of 3.9B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while VCYT trades at $48.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas VCYT's P/E ratio is 23.97. In terms of profitability, WAT's ROE is +0.02%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, WAT is more volatile compared to VCYT. This indicates higher risk in terms of short-term price fluctuations for WAT.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
WAT vs CDNA Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, CDNA has a market cap of 3.6B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while CDNA trades at $69.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas CDNA's P/E ratio is 82.39. In terms of profitability, WAT's ROE is +0.02%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, WAT is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for WAT.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
WAT vs OLK Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas OLK's P/E ratio is -96.59. In terms of profitability, WAT's ROE is +0.02%, compared to OLK's ROE of -0.07%. Regarding short-term risk, WAT is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for WAT.Check OLK's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
WAT vs NEO Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, NEO has a market cap of 2.2B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while NEO trades at $16.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas NEO's P/E ratio is 127.62. In terms of profitability, WAT's ROE is +0.02%, compared to NEO's ROE of -0.06%. Regarding short-term risk, WAT is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for WAT.Check NEO's competition here
Personalis, Inc. (NASDAQ: PSNL)
WAT vs PSNL Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while PSNL trades at $15.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas PSNL's P/E ratio is -14.52. In terms of profitability, WAT's ROE is +0.02%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, WAT is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for WAT.Check PSNL's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
WAT vs WGS Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, WGS has a market cap of 1.7B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while WGS trades at $62.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas WGS's P/E ratio is 155.97. In terms of profitability, WAT's ROE is +0.02%, compared to WGS's ROE of -0.39%. Regarding short-term risk, WAT is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for WAT.Check WGS's competition here
OPKO Health, Inc. (NASDAQ: OPK)
WAT vs OPK Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while OPK trades at $1.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas OPK's P/E ratio is -18.33. In terms of profitability, WAT's ROE is +0.02%, compared to OPK's ROE of -0.06%. Regarding short-term risk, WAT is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for WAT.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
WAT vs CSTL Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, CSTL has a market cap of 1B. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while CSTL trades at $33.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas CSTL's P/E ratio is -50.12. In terms of profitability, WAT's ROE is +0.02%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, WAT is more volatile compared to CSTL. This indicates higher risk in terms of short-term price fluctuations for WAT.Check CSTL's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
WAT vs GRALV Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas GRALV's P/E ratio is N/A. In terms of profitability, WAT's ROE is +0.02%, compared to GRALV's ROE of N/A. Regarding short-term risk, WAT is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for WAT.Check GRALV's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
WAT vs MYGN Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, MYGN has a market cap of 557.6M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while MYGN trades at $5.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas MYGN's P/E ratio is -44.85. In terms of profitability, WAT's ROE is +0.02%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, WAT is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for WAT.Check MYGN's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
WAT vs FLGT Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, FLGT has a market cap of 553.1M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while FLGT trades at $20.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas FLGT's P/E ratio is 2010.00. In terms of profitability, WAT's ROE is +0.02%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, WAT is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for WAT.Check FLGT's competition here
Global Cord Blood Corporation (NYSE: CO)
WAT vs CO Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas CO's P/E ratio is 5.06. In terms of profitability, WAT's ROE is +0.02%, compared to CO's ROE of +0.11%. Regarding short-term risk, WAT is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for WAT.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
WAT vs FLDM Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas FLDM's P/E ratio is -4.74. In terms of profitability, WAT's ROE is +0.02%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, WAT is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for WAT.Check FLDM's competition here
Exagen Inc. (NASDAQ: XGN)
WAT vs XGN Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, XGN has a market cap of 176.1M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while XGN trades at $7.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas XGN's P/E ratio is -8.98. In terms of profitability, WAT's ROE is +0.02%, compared to XGN's ROE of -1.22%. Regarding short-term risk, WAT is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for WAT.Check XGN's competition here
Biodesix, Inc. (NASDAQ: BDSX)
WAT vs BDSX Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, BDSX has a market cap of 172.4M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while BDSX trades at $21.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas BDSX's P/E ratio is -6.68. In terms of profitability, WAT's ROE is +0.02%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, WAT is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for WAT.Check BDSX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
WAT vs GTH Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas GTH's P/E ratio is -1.11. In terms of profitability, WAT's ROE is +0.02%, compared to GTH's ROE of -1.01%. Regarding short-term risk, WAT is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for WAT.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
WAT vs GENE Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas GENE's P/E ratio is -38.25. In terms of profitability, WAT's ROE is +0.02%, compared to GENE's ROE of -1.85%. Regarding short-term risk, WAT is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for WAT.Check GENE's competition here
Freenome, Inc. (NASDAQ: FRNM)
WAT vs FRNM Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, FRNM has a market cap of 104.2M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while FRNM trades at $12.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas FRNM's P/E ratio is N/A. In terms of profitability, WAT's ROE is +0.02%, compared to FRNM's ROE of N/A. Regarding short-term risk, WAT is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for WAT.Check FRNM's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
WAT vs IMDX Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, IMDX has a market cap of 92.6M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while IMDX trades at $2.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas IMDX's P/E ratio is -1.90. In terms of profitability, WAT's ROE is +0.02%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, WAT is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for WAT.Check IMDX's competition here
Precipio, Inc. (NASDAQ: PRPO)
WAT vs PRPO Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, PRPO has a market cap of 37.1M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while PRPO trades at $19.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas PRPO's P/E ratio is -31.92. In terms of profitability, WAT's ROE is +0.02%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, WAT is more volatile compared to PRPO. This indicates higher risk in terms of short-term price fluctuations for WAT.Check PRPO's competition here
Akumin Inc. (NASDAQ: AKU)
WAT vs AKU Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas AKU's P/E ratio is -0.13. In terms of profitability, WAT's ROE is +0.02%, compared to AKU's ROE of -5.32%. Regarding short-term risk, WAT is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for WAT.Check AKU's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
WAT vs QUCY Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, QUCY has a market cap of 23M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while QUCY trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas QUCY's P/E ratio is -0.05. In terms of profitability, WAT's ROE is +0.02%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, WAT is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for WAT.Check QUCY's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
WAT vs BIAF Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, BIAF has a market cap of 17.6M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while BIAF trades at $2.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas BIAF's P/E ratio is -0.33. In terms of profitability, WAT's ROE is +0.02%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, WAT is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for WAT.Check BIAF's competition here
MDxHealth S.A. (NASDAQ: MDXH)
WAT vs MDXH Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, MDXH has a market cap of 17.5M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while MDXH trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas MDXH's P/E ratio is -0.25. In terms of profitability, WAT's ROE is +0.02%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, WAT is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for WAT.Check MDXH's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
WAT vs CEMI Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas CEMI's P/E ratio is -0.63. In terms of profitability, WAT's ROE is +0.02%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, WAT is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for WAT.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
WAT vs ENZ Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas ENZ's P/E ratio is -2.24. In terms of profitability, WAT's ROE is +0.02%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, WAT is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for WAT.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
WAT vs PMD Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas PMD's P/E ratio is -5.24. In terms of profitability, WAT's ROE is +0.02%, compared to PMD's ROE of -0.32%. Regarding short-term risk, WAT is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for WAT.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
WAT vs ME Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas ME's P/E ratio is -0.03. In terms of profitability, WAT's ROE is +0.02%, compared to ME's ROE of -3.47%. Regarding short-term risk, WAT is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for WAT.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
WAT vs MYNZ Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, WAT's ROE is +0.02%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, WAT is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for WAT.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
WAT vs BNR Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, BNR has a market cap of 12.5M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while BNR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas BNR's P/E ratio is -13.59. In terms of profitability, WAT's ROE is +0.02%, compared to BNR's ROE of -0.13%. Regarding short-term risk, WAT is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for WAT.Check BNR's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
WAT vs CHEK Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas CHEK's P/E ratio is -0.43. In terms of profitability, WAT's ROE is +0.02%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, WAT is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for WAT.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
WAT vs CNTG Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas CNTG's P/E ratio is -0.23. In terms of profitability, WAT's ROE is +0.02%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, WAT is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for WAT.Check CNTG's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
WAT vs APDN Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas APDN's P/E ratio is -0.10. In terms of profitability, WAT's ROE is +0.02%, compared to APDN's ROE of -7.23%. Regarding short-term risk, WAT is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for WAT.Check APDN's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
WAT vs NDRA Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, NDRA has a market cap of 7.1M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while NDRA trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas NDRA's P/E ratio is -0.70. In terms of profitability, WAT's ROE is +0.02%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, WAT is more volatile compared to NDRA. This indicates higher risk in terms of short-term price fluctuations for WAT.Check NDRA's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
WAT vs BIAFW Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, BIAFW has a market cap of 5.7M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while BIAFW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas BIAFW's P/E ratio is 0.61. In terms of profitability, WAT's ROE is +0.02%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, WAT is more volatile compared to BIAFW. This indicates higher risk in terms of short-term price fluctuations for WAT.Check BIAFW's competition here
Invitae Corporation (NYSE: NVTA)
WAT vs NVTA Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas NVTA's P/E ratio is -0.00. In terms of profitability, WAT's ROE is +0.02%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, WAT is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for WAT.Check NVTA's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
WAT vs ADVB Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, ADVB has a market cap of 5.2M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while ADVB trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas ADVB's P/E ratio is -28.82. In terms of profitability, WAT's ROE is +0.02%, compared to ADVB's ROE of -0.20%. Regarding short-term risk, WAT is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for WAT.Check ADVB's competition here
LumiraDx Limited (NASDAQ: LMDXW)
WAT vs LMDXW Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, WAT's ROE is +0.02%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, WAT is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for WAT.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
WAT vs LMDX Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas LMDX's P/E ratio is -0.01. In terms of profitability, WAT's ROE is +0.02%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, WAT is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for WAT.Check LMDX's competition here
DermTech, Inc. (NASDAQ: DMTK)
WAT vs DMTK Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas DMTK's P/E ratio is -0.04. In terms of profitability, WAT's ROE is +0.02%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, WAT is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for WAT.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
WAT vs NOTV Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas NOTV's P/E ratio is -0.03. In terms of profitability, WAT's ROE is +0.02%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, WAT is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for WAT.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
WAT vs SQL Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas SQL's P/E ratio is -0.40. In terms of profitability, WAT's ROE is +0.02%, compared to SQL's ROE of -30.46%. Regarding short-term risk, WAT is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for WAT.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
WAT vs AWH Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas AWH's P/E ratio is -0.09. In terms of profitability, WAT's ROE is +0.02%, compared to AWH's ROE of +1.62%. Regarding short-term risk, WAT is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for WAT.Check AWH's competition here
iSpecimen Inc. (NASDAQ: ISPC)
WAT vs ISPC Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, ISPC has a market cap of 2.1M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while ISPC trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas ISPC's P/E ratio is -0.03. In terms of profitability, WAT's ROE is +0.02%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, WAT is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for WAT.Check ISPC's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
WAT vs HTGM Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas HTGM's P/E ratio is -0.03. In terms of profitability, WAT's ROE is +0.02%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, WAT is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for WAT.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
WAT vs BIOC Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas BIOC's P/E ratio is -0.01. In terms of profitability, WAT's ROE is +0.02%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, WAT is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for WAT.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
WAT vs SQLLW Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, WAT's ROE is +0.02%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, WAT is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for WAT.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
WAT vs WGSWW Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, WAT's ROE is +0.02%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, WAT is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for WAT.Check WGSWW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
WAT vs OCDX Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas OCDX's P/E ratio is -42.28. In terms of profitability, WAT's ROE is +0.02%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, WAT is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for WAT.Check OCDX's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
WAT vs CHEKZ Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, WAT's ROE is +0.02%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, WAT is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for WAT.Check CHEKZ's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
WAT vs BNGOW Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas BNGOW's P/E ratio is N/A. In terms of profitability, WAT's ROE is +0.02%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, WAT is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for WAT.Check BNGOW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
WAT vs MEUSW Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas MEUSW's P/E ratio is N/A. In terms of profitability, WAT's ROE is +0.02%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, WAT is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for WAT.Check MEUSW's competition here
Danaher Corporation (NYSE: DHR-PA)
WAT vs DHR-PA Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, WAT's ROE is +0.02%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, WAT is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for WAT.Check DHR-PA's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
WAT vs NDRAW Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas NDRAW's P/E ratio is N/A. In terms of profitability, WAT's ROE is +0.02%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, WAT is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for WAT.Check NDRAW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
WAT vs PRXL Comparison October 2026
Waters Corporation (NYSE: WAT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 44.5B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, WAT is priced at $460.34 on the NYSE, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 33.16, whereas PRXL's P/E ratio is 42.97. In terms of profitability, WAT's ROE is +0.02%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, WAT is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for WAT.Check PRXL's competition here